NCT05007522View on ClinicalTrials.gov

Ketotifen and Indomethacin Combination Treatment Clinical Trial for COVID-19

PHASE3CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

May 3, 2022

Primary Completion Date

June 20, 2024

Study Completion Date

June 20, 2024

Conditions
COVID-19 Respiratory Infection
Interventions
DRUG

Ketotifen/Indomethacin

2 mg tablet, 75 mg SR tablet

DRUG

Placebo

Matching placebo tablet

Trial Locations (2)

44600

Global Clinical Research Pvt. Ltd., Kathmandu

Unknown

Dhulikhel Hospital, Kavre

Sponsors
All Listed Sponsors
collaborator

National University of Singapore

OTHER

lead

Sen-Jam Pharmaceutical

OTHER

NCT05007522 - Ketotifen and Indomethacin Combination Treatment Clinical Trial for COVID-19 | Biotech Hunter | Biotech Hunter